Novo's new strategy hinges on something it can't manufacture: investor trust
Why now
Thesis: Novo's strategy depends on rebuilding investor confidence
Catalyst to watch: Pipeline data or guidance updates
Main risk: Sentiment stays negative, funding tightens
Why it matters
Investor skepticism can raise Novo's cost of capital and constrain its ability to fund a broadened pipeline strategy.
Details
Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
Sources
- cnbc · 2026-09-24 06:20 UTC